INKT MiNK Therapeutics Inc
593
$0.9459
$0.0052
(0.55%)
| Watchers | 593 |
| 52-Wk Low | $0.75 |
| 52-Wk High | $3.34 |
| Market Cap | $32.64M |
| Volume | 10,497.00 |
| 52-Wk High | $3.34 |
| 52-Wk Low | $0.75 |
HC Wainwright Lowers MiNK Therapeutics (NASDAQ:INKT) Price Target to $9.00Zolmax • about 2 months ago
MiNK Therapeutics (NASDAQ:INKT Free Report) had its target price reduced by HC Wainwright from $10.00 to $9.00 in a report released on Thursday morning, Benzinga reports. They currently have...
Share to Feed
Related Stocks: NAS:INKT...
Launched and enrolling Phase 2 trial of allo-iNKTs with botensilimab/balstilimab and chemotherapy in second-line gastroesophageal cancers Announced collaboration with Immunoscape for development...
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases ModelNEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage...
MiNK Therapeutics, Inc. (NASDAQ:INKT Get Free Report) was the recipient of a significant drop in short interest in the month of February. As of February 15th, there was short interest...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Dr. Yelena Janjigian, Chief of GI Cancers, Leads Investigator Sponsored Study at Memorial Sloan Kettering Cancer CenterTrial is Supported by Stand Up To Cancer as Part of an Initiative to Find...